Novelix Pharmaceuticals Ltd
₹ 78.3
2.49%
21 Aug
- close price
About
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Key Points
- Market Cap ₹ 223 Cr.
- Current Price ₹ 78.3
- High / Low ₹ 92.0 / 38.0
- Stock P/E 61.6
- Book Value ₹ 22.0
- Dividend Yield 0.00 %
- ROCE 9.98 %
- ROE 8.00 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Promoter holding has increased by 4.86% over last quarter.
- Company's median sales growth is 42.1% of last 10 years
- Company's working capital requirements have reduced from 222 days to 122 days
Cons
- Stock is trading at 3.55 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.12% over last 3 years.
- Company has high debtors of 163 days.
- Promoter holding has decreased over last 3 years: -12.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 4 | 3 | 4 | 2 | 1 | 1 | 2 | 4 | 31 | 132 | 147 | |
| 1 | 1 | 3 | 3 | 3 | 1 | 4 | 3 | 2 | 4 | 31 | 129 | 142 | |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | -0 | 0 | 3 | 5 |
| OPM % | 33% | 43% | 5% | 15% | 6% | 12% | -244% | -151% | 0.0% | -6% | 0.5% | 2.6% | 3.1% |
| 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | -0 | 0 | 0 | 3 | 4 |
| Tax % | 88% | 31% | 24% | 34% | -32% | 20% | 0% | -1% | 0% | 50% | 33% | 25% | |
| 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | -0 | 0 | 0 | 3 | 4 | |
| EPS in Rs | 0.02 | 0.12 | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.08 | 1.21 | 1.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 152% |
| 3 Years: | 310% |
| TTM: | 180% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 23% |
| 3 Years: | 255% |
| TTM: | 535% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 61% |
| 3 Years: | 105% |
| 1 Year: | 94% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 21 |
| Reserves | 3 | 3 | 3 | 4 | 4 | 4 | 1 | -1 | -1 | -1 | 8 | 25 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 42 | |
| Total Liabilities | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 3 | 2 | 3 | 3 | 4 | 4 | 1 | 3 | 3 | 0 | 0 |
| 9 | 8 | 9 | 9 | 9 | 8 | 5 | 5 | 4 | 4 | 27 | 89 | |
| Total Assets | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 2 | -1 | 1 | -0 | 1 | 1 | 1 | -2 | -0 | -14 | -22 | |
| -0 | -2 | 1 | -1 | 0 | -0 | 0 | 0 | 0 | 0 | 3 | -2 | |
| -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 26 | |
| Net Cash Flow | -1 | 0 | -0 | -0 | 0 | 1 | 1 | 1 | -2 | -0 | 1 | 2 |
| Free Cash Flow | -1 | 2 | -1 | 1 | -0 | 1 | 0 | -1 | -2 | -0 | -14 | -26 |
| CFO/OP | -90% | 472% | -535% | 225% | -220% | 672% | -18% | -34% | 136% | -9,771% | -643% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 4 | 40 | 130 | 216 | 19 | 25 | 32 | 36 | 1 | 216 | 163 |
| Inventory Days | 0 | 28 | 19 | 13 | 39 | 89 | 239 | 222 | 113 | 10 | 42 | |
| Days Payable | 0 | 54 | 13 | 5 | 4 | 0 | 14 | 0 | 115 | 116 | ||
| Cash Conversion Cycle | 30 | 4 | 68 | 95 | 216 | 54 | 111 | 271 | 244 | 114 | 111 | 88 |
| Working Capital Days | 2,225 | 2,584 | 863 | 932 | 858 | 1,711 | 819 | 647 | 743 | 346 | 197 | 122 |
| ROCE % | 1% | 1% | 1% | 3% | 1% | 1% | -31% | -19% | -1% | 0% | 1% | 10% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Closing stock of goods (pharma inventory) INR '000 |
|
|||||||||
| Foods Business revenue share % |
||||||||||
| Pharma Business revenue share % |
||||||||||
| Trading in Shares revenue share % |
||||||||||
| Closing stock of securities (shares inventory) INR '000 |
||||||||||
| Number of permanent employees on rolls count |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement Under Regulation 30 (LODR) - Lease Deed
- Novelix signed 5-year land lease for micro algae cultivation and glass reactor systems in Telangana.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of Newspaper Publication of the financial results for the quarter ended 30th June, 2026.
-
Compliances- Statement Of Deviation & Variation
- Filed quarterly statement of deviation/variation; no deviation, Rs 421.50 lakh utilized for long-term funding needs.
- Results- Financial Results For June 30, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, 13Th August, 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
- Board approved Q1 FY2026-27 standalone results; revenue 3,691.51 lakh, profit 117.89 lakh.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1][2][3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.